High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy
- PMID: 23542406
- DOI: 10.1016/j.juro.2013.03.078
High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy
Abstract
Purpose: We clarified the diagnostic ability of multiparametric magnetic resonance imaging to reveal anterior cancer missed by transrectal 12-core prostate biopsy based on the results of 3-dimensional 26-core prostate biopsy, which is a combination of transrectal 12-core and transperineal 14-core biopsies.
Materials and methods: The study population consisted of 324 patients who prospectively underwent prebiopsy multiparametric magnetic resonance imaging and then 3-dimensional 26-core prostate biopsy at a single institution. We defined transrectal 12-core negative cancer as cancer detected by transperineal 14-core but not transrectal 12-core prostate biopsy. We focused on cancer in the anterior region. Any findings suspicious for malignancy in the region anterior to the urethra on multiparametric magnetic resonance imaging were defined as an anterior lesion on imaging. Significant cancer was defined as a biopsy Gleason score of 4 + 3 or greater, a greater than 20% positive core and/or a maximum cancer length of 5 mm or greater. Associations between an anterior lesion on imaging and transrectal 12-core negative cancer were investigated.
Results: The overall cancer detection rate on 3-dimensional 26-core prostate biopsy was 39% (128 of 324 cases), of which 28% (36 of 128) were transrectal 12-core negative cancers. An anterior lesion on prebiopsy multiparametric magnetic resonance imaging was identified in 20% of men overall (65 of 324). Of men with and without an anterior lesion on imaging 40% (26 of 65) and 3.8% (10 of 259), respectively, had transrectal 12-core negative cancer. Significant transrectal 12-core negative cancer was observed in 0.4% (1 of 259 men) without an anterior lesion on imaging. Prebiopsy multiparametric magnetic resonance imaging revealed an anterior lesion in 92% of cases (11 of 12) of significant transrectal 12-core negative cancer.
Conclusions: Prebiopsy multiparametric magnetic resonance imaging has the potential to efficiently select men who could advantageously undergo anterior samplings, in addition to transrectal 12-core prostate biopsy.
Keywords: 3-dimensional 26-core prostate biopsy; 3D26PBx; DCEI; DRE; DWI; MP-MRI; MRI; PCa; PSA; T2-weighted imaging; T2WI; TP14PBx; TR12; TR12 prostate biopsy; TR12PBx; biopsy; diagnosis; diagnostic imaging; diffusion-weighted imaging; digital rectal examination; dynamic contrast enhanced imaging; magnetic resonance imaging; multiparametric MRI; prostate; prostate cancer; prostate specific antigen; transperineal 14-core prostate biopsy; transrectal 12-core.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Editorial comment.J Urol. 2013 Sep;190(3):873. doi: 10.1016/j.juro.2013.03.129. Epub 2013 Jun 10. J Urol. 2013. PMID: 23763863 No abstract available.
Similar articles
-
Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.J Urol. 2013 Aug;190(2):502-8. doi: 10.1016/j.juro.2013.02.3197. Epub 2013 Mar 7. J Urol. 2013. PMID: 23473904
-
Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.J Urol. 2013 Oct;190(4):1380-6. doi: 10.1016/j.juro.2013.04.043. Epub 2013 Apr 19. J Urol. 2013. PMID: 23608676 Clinical Trial.
-
Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.Cancer. 2014 Sep 15;120(18):2876-82. doi: 10.1002/cncr.28790. Epub 2014 Jun 10. Cancer. 2014. PMID: 24917122
-
Multiparametric magnetic resonance imaging in the detection of prostate cancer.Aktuelle Urol. 2014 Mar;45(2):119-26. doi: 10.1055/s-0034-1371875. Epub 2014 Apr 3. Aktuelle Urol. 2014. PMID: 24700068 Review.
-
Prebiopsy magnetic resonance spectroscopy and imaging in the diagnosis of prostate cancer.Int J Urol. 2012 Jul;19(7):602-13. doi: 10.1111/j.1442-2042.2012.02995.x. Epub 2012 Mar 21. Int J Urol. 2012. PMID: 22435389 Review.
Cited by
-
Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance.Prostate Cancer Prostatic Dis. 2015 Sep;18(3):288-96. doi: 10.1038/pcan.2015.29. Epub 2015 Jun 16. Prostate Cancer Prostatic Dis. 2015. PMID: 26078202
-
Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.BJU Int. 2014 Dec;114(6b):E120-E129. doi: 10.1111/bju.12771. Epub 2014 Aug 13. BJU Int. 2014. PMID: 24731026 Free PMC article.
-
Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline.Can Urol Assoc J. 2017 Jan-Feb;11(1-2):E1-E7. doi: 10.5489/cuaj.3968. Epub 2017 Jan 12. Can Urol Assoc J. 2017. PMID: 28163805 Free PMC article.
-
Diffusion weighted imaging of the prostate-principles, application, and advances.Transl Androl Urol. 2017 Jun;6(3):490-498. doi: 10.21037/tau.2017.05.06. Transl Androl Urol. 2017. PMID: 28725591 Free PMC article. Review.
-
Detection of anterior prostate cancer using a magnetic resonance imaging-transrectal ultrasound fusion biopsy in cases with initial biopsy and history of systematic biopsies.Prostate Int. 2023 Dec;11(4):212-217. doi: 10.1016/j.prnil.2023.08.002. Epub 2023 Aug 31. Prostate Int. 2023. PMID: 38196555 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous